Navigation Links
China Pharma Holdings, Inc. Announces Clinical Trials Already Underway for Candesartan
Date:2/11/2009

HAIKOU CITY, China, Feb. 11 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, announced today that the company has initiated clinical trials for the generic version of the leading hypertension drug Candesartan.

The clinical trials for this product are anticipated to require approximately 18 months to complete. The sartan group of drugs, used as front- line therapy in the treatment of hypertension, are usually well-tolerated, and have a high safety record. Candesartan was discovered and originally synthesized by the Japanese firm, Takeda Pharmaceutical Company Limited and jointly developed by the same company with AstraZeneca. Worldwide sales for 2007 exceeded $2.5 billion(1). In China, Candesartan is listed on the National Basic Medical Insurance Drug List, enabling patient reimbursement.

China Pharma's CEO and president, Ms Zhilin Li, commented, ''In China today, nearly 60% of all urban adults aged 65 years and over suffer from hypertension(2). Moreover, due to the aging of the population and changes in lifestyle, the urban prevalence of hypertension has been predicted to grow to 100 million by 2011(2). Even in 2004, sales in China of anti-hypertension drugs exceeded CNY 10 billion ($1.2 billion, Dec. 2004), exhibiting a market growth of over 30% year on year, and accounting for 22% of all cardiovascular system drugs sold in China(3). Hypertension is a serious problem and is linked to an increased incidence of other diseases, particularly brain edema, coronary heart disease and diabetes. Candesartan is a well established hypertension drug and is known to be particularly suitable for heart failure and diabetic patients. Our R&D strategy is to enable us to provide more effective treatment for the high numbers of patients in China whose medication needs are serious
'/>"/>

SOURCE China Pharma Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
2. Syngenta Enters Into Research Collaboration With Anhui Academy, China
3. China Sky One Medical, Inc. CFO to Present at Roth Conference
4. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
5. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
6. China-Biotics, Inc. Receives Manufacturing Certificate for New Products
7. China Biologic Products Enters into Short-Term Loan Agreement
8. China Pharma Holdings, Inc. Receives SFDA Production Approval for Tiopronin Enteric-Coated Capsules
9. American Oriental Bioengineering to Participate in the 2009 UBS Greater China Conference
10. China Sky One Medical, Inc. Qualifies for Preferential Income Tax Rate
11. Health Robotics Announces Partnership in the Peoples Republic of China With The Devon International Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... LAS VEGAS , July 31, 2015 /PRNewswire/ ... pharmacists seek resources that help them drive positive ... as a vital source of patient care in ... Pharmacy,s annual tradeshow and conference, AmerisourceBergen announced ... strengthen its Pharmacy Services Administration Organization and help ...
(Date:7/30/2015)... ATLANTA , July 30, 2015 ... leaders to the 2015 AACC Annual Meeting & ... from July 26–30. The meeting showcased revolutionary ... improves the ability of healthcare providers to diagnose ... get effective medical treatment. As ...
(Date:7/30/2015)... , CA (PRWEB) , ... July 30, 2015 ... ... the successful completion of a field clinical study of its canine osteoarthritis stem ... together with Aratana Therapeutics (Kansas City, KS) and will be marketed in the ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against the ... $697 million compared to $701 million in the second ... changes in foreign currency exchange rates decreased sales by ... By business unit, organic sales growth was 6% in ... , Reported diluted EPS was $0.98 compared to ...
Breaking Biology Technology:AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... FRAZER, Pa. and PHILADELPHIA, Oct. 21 ,Cephalon, Inc. ... EURX ) today announced,receipt of a Paragraph ... an Abbreviated New Drug Application (ANDA) submitted to ... Pharmaceuticals, Inc.,requesting approval to market and sell a ...
... ARBOR, Mich., Oct. 21 Terumo Heart, Inc. ... Left Ventricular,Assist System (LVAS), marking an important early ... by Dr. Francis Pagani performed the five implants,at ... Arbor with three,of the surgeries performed off-pump., ...
... the Trial,s First Stage ... Objective Tumor Responses- -Patient ... Oct. 21 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical ... announced that updated preliminary data from the first,stage of its Phase ...
Cached Biology Technology:Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 2Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 3Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 4Fifth DuraHeart(TM) U.S. Implant Marks Important Milestone in U.S. Pivotal Trial 2Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 4
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
(Date:7/8/2015)... Summary Pancreatic cancer is the 12th ... with a mortality rate of 10.9 deaths per 100,000 ... patients has highlighted a significant need for new and ... by the current market. A highly active pancreatic ... molecule types and mechanisms of action, which provides a ...
(Date:7/8/2015)... 8, 2015 The consumer products industry ... must have products such as wearables, smart wallets & other ... biometrics based devices continues to rapidly grow.  Biometrics & Wearable ... NXTD ), Google Inc. (NASDAQ: GOOG ), Apple Inc. ... GoPro, Inc. (NASDAQ: GPRO ) and Baidu Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6
... in the United Kingdom and the Netherlands are ... progressively more resistant to antibiotics over the last ... more stringent rules on use of antibiotics in ... that broadly improves water quality in surrounding environments. ...
... 3, 2010) A scientific "Renaissance man" whose ... and polymer physics, Erez Lieberman-Aiden, graduate student at ... has been named the winner of the prestigious ... 2010 $30,000 Lemelson-MIT Collegiate Student Prize winners announced ...
... Blacksburg, Va. Poor air quality apparently affects the ... by Virginia Tech civil and environmental engineer Linsey Marr. ... race results, weather data, and air pollutant concentrations in seven ... top three male and female finishing times were compared with ...
Cached Biology News:MIT student inventor honored for transformative work in genomics and linguistics 2MIT student inventor honored for transformative work in genomics and linguistics 3Women more affected than men by air pollution when running marathons 2
... Now, for the first time, you ... faster and more efficiently without interferences. The ... to remove unwanted, multiple high-abundant proteins from ... with just one device. With this ...
... Chemicon Select Tissue Arrays are intended ... individual tissues were fixed in neutral buffered ... identification and diagnosis was performed by certified ... their paraffin blocks and relocated into a ...
... The Agilent Two-Color RNA Spike-In Kit contains ... anneal only to complementary control probes on ... The spike-ins serve as a positive microarray ... NOTE: This kit is a required ...
... the industry standard microarray image analysis software ... and analysis tools, visualizations, automation capabilities, performance ... included with every GenePix scanner, and it ... and all types of arrays. A wide ...
Biology Products: